Rezolute (RZLT) Non-Current Debt (2018 - 2022)

Rezolute (RZLT) reported Non-Current Debt of $14.3 million for Q1 2022, up 0.76% sequentially from $14.2 million in Q4 2021.

Rezolute (RZLT) Non-Current Debt (2018 - 2022) Analysis & Trends

Rezolute (RZLT) has 3 years of Non-Current Debt data on file, last reported at $14.3 million in Q1 2022.

For the quarter ending Q1 2022, Non-Current Debt changed N/A year-over-year to $14.3 million; the trailing twelve-month figure through Mar 2022 stood at $14.3 million (changed N/A YoY), and the FY2021 full-year result was $14.0 million, changed N/A from the prior year.
Non-Current Debt climbed to $14.3 million in Q1 2022, from $14.2 million in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $14.3 million in Q1 2022 to a low of $767519.0 in Q2 2018.
A 3-year average of $10.6 million and a median of $14.0 million in 2021 frame the typical range for Non-Current Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	105.94 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	842.92 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Rezolute	31,153.77	31,153.77	-	-

Download Data